Lipidomic Signatures Informs Intravenous Racemic Ketamine Associated Remission in Treatment-Resistant Depression: A Pilot Study

被引：0
|
作者：
Singh, Balwinder [1 ]
MahmoudianDehkordi, Siamak [1 ]
Voort, Jennifer Vande [1 ]
Han, Xianlin [1 ]
Port, John [1 ]
Frye, Mark [1 ]
Daouk, Rima Kaddurah [1 ]
机构：
[1] Mayo Clin, Coll Med, Rochester, MN USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2022年 / 47卷
关键词：
IV; Ketamine; Metabolomics Signature; Treatment; Resistant Depression; Open Label Trials;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
P227
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [1] Lipidomic Signatures Informs Intravenous Racemic Ketamine Associated Remission in Treatment-Resistant Depression: A Pilot Study
    Singh, Balwinder
    MahmoudianDehkordi, Siamak
    Vande Voort, Jennifer
    Han, Xianlin
    Port, John
    Frye, Mark
    Daouk, Rima Kaddurah
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 (SUPPL 1) : 192 - 192
  • [2] Lipidomic Signatures Inform Intravenous Racemic Ketamine Associated Remission in Treatment-Resistant Depression: A Feasibility Trial
    Singh, Balwinder
    MahmoudianDehkordi, Siamak
    Voort, Jennifer Vande
    Han, Xianlin
    Port, John
    Frye, Mark
    Kaddurah-Daouk, Rima
    BIOLOGICAL PSYCHIATRY, 2023, 93 (09) : S23 - S24
  • [3] Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study
    Singh, Balwinder
    MahmoudianDehkordi, Siamak
    Vande Voort, Jennifer L.
    Han, Xianlin
    Port, John D.
    Frye, Mark A.
    Kaddurah-Daouk, Rima
    PSYCHIATRY RESEARCH, 2022, 314
  • [4] INTRAVENOUS KETAMINE FOR TREATMENT-RESISTANT DEPRESSION IN ADOLESCENTS?
    Cullen, Kathryn R.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2016, 55 (10): : S284 - S284
  • [5] Remission of Treatment-Resistant Depression With Electroconvulsive Therapy and Ketamine
    Niemegeers, Peter
    Schrijvers, Didier
    Madani, Yamina
    Sabbe, Bernard G. C.
    JOURNAL OF ECT, 2014, 30 (03) : E31 - E32
  • [6] A Case of Tachyphylaxis After Long-Term Intravenous Racemic Ketamine for Treatment-Resistant Depression
    Cavalcanti, Stefanie
    Lopez, Olga A.
    Kung, Simon
    Vande Voort, Jennifer L.
    Somers, Kristin
    Frye, Mark A.
    Singh, Balwinder
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2024, 44 (03) : 313 - 314
  • [7] Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression
    Rivas-Grajales, Ana Maria
    Salas, Ramiro
    Robinson, Meghan E.
    Qi, Karen
    Murrough, James W.
    Mathew, Sanjay J.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2021, 24 (05): : 383 - 391
  • [8] A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression
    Pattanaseri, Keerati
    Lortrakul, Juthawadee
    Jaisin, Kankamol
    Srifuengfung, Maytinee
    Sa-nguanpanich, Naratip
    Viravan, Natee
    Pariwatcharakul, Pornjira
    Makarasara, Wattanan
    Ratta-apha, Woraphat
    BMC PSYCHIATRY, 2024, 24 (01)
  • [9] Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series
    Tham, Joseph C. W.
    Do, Andre
    Fridfinnson, Jason
    Rafizadeh, Reza
    Siu, Jacky T. P.
    Budd, George P.
    Lam, Raymond W.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2022, 37 (05) : 206 - 214
  • [10] Racemic ketamine treatment attenuates anterior cingulate cortex GABA deficits among remitters in treatment-resistant depression: A pilot study
    Singh, Balwinder
    Port, John D.
    Pazdernik, Vanessa
    Coombes, Brandon J.
    Voort, Jennifer L. Vande
    Frye, Mark A.
    PSYCHIATRY RESEARCH-NEUROIMAGING, 2022, 320
12345